{"id":8,"date":"2023-11-28T09:10:59","date_gmt":"2023-11-28T09:10:59","guid":{"rendered":"http:\/\/gebro.es\/?page_id=8"},"modified":"2024-02-29T19:11:58","modified_gmt":"2024-02-29T19:11:58","slug":"about","status":"publish","type":"page","link":"https:\/\/gebro.es\/en\/about\/","title":{"rendered":"About Gebro"},"content":{"rendered":"
\n
\n \"\"\n <\/div>\n
<\/div>\n
\n
\n
\n

About Gebro<\/h1>\n <\/div>\n
\n
\n

At Gebro Pharma we strive day by day to improve people\u2019s health and quality of life by combining science, innovation and talent.<\/p>\n\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n

\n
<\/i><\/a><\/span><\/span><\/div>\n<\/section>\n\n\n
\n
\n
\n

Company Overview<\/h2>\n <\/div>\n
\n

Laboratorios Gebro Pharma<\/strong> is a pharmaceutical company belonging to the Austrian holding Gebro GmbH<\/strong>, made up of a group of companies focused on health and life.<\/p>\n

The Gebro Holding, owned by the Broschek family, started its activity in the mountains of Tyrol in 1947 and its subsidiary in Spain opened its doors in 2002.<\/p>\n

Laboratorios Gebro Pharma markets and distributes prescription drugs within different therapeutic areas<\/strong>, and at the same time contributes to the Spanish National Public Health System with scientific and medical research projects<\/strong>. Constant innovation in products and services and the search for new solutions that help a more sustainable world in health are our reason for being.<\/p>\n

Gebro Spain counts with 30 drugs currently in portfolio<\/strong>, a pipeline of 7 products<\/strong>, is collaborating with over 30 industry partners<\/strong> in several countries, 12 scientific-medical research projects, is attached to the Profarma Plan since 2016<\/strong>, is certified as a Great Place To Work<\/strong>, a partner of the Barcelona Health Hub and part of Farmaindustria.<\/p>\n\n <\/div>\n <\/div>\n

\n
\n \"\"\n <\/div>\n
\n \"\"\n <\/div>\n
\n \"\"\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n
\n
\n
\n

Pascal Broschek<\/h2>\n

President of the Gebro Holding GmbH group<\/p>\n <\/div>\n

\n <\/svg>\n <\/div>\n
\n

I\u2019m delighted to welcome you<\/strong> and introduce you<\/strong> to the meeting point between Austria and Spain which has given birth to Gebro Pharma.<\/p>\n

Gebro Pharma is \u201cThe Laboratory from the Alps\u201d<\/strong>, a family company from the heart of Tyrol with a presence in Spain, where both countries\u2019 culture and values come together. We believe that what unites us is stronger than what separates us. With that in mind we nurture and encourage what we have in common and embrace the differences that enrich us.<\/p>\n

Life is beautiful in its diversity and we should ensure that we respect, value and integrate that plurality into our daily lives. By doing this, we make the best of ourselves.<\/p>\n

We encourage health professionals, patients, partners and collaborators to browse our website to learn more about our commitment: because we care about life, we work to find solutions that improve people\u2019s health.<\/strong><\/p>\n\n <\/div>\n <\/div>\n <\/div>\n

\n \"\"\n <\/div>\n<\/section>\n\n\n
\n

Purpose, mission and values<\/h2>\n
\n \n
\n \n
\n
\n
\n
\n
\n

Purpose<\/h2>\n
\n 1<\/span>\n \/\n 3<\/span>\n <\/div>\n <\/div>\n

At Gebro Pharma our purpose is to improve the health and quality of life of patients, the people who assist them and the health professionals<\/strong> who care for them through pharmacological solutions and services that also contribute to a sustainable development.<\/p>\n

We work with research centers and institutes, startups and opinion leaders with the aim of strengthening and promoting research activity in our country. Our aim is to try to optimize what already exists, to identify possible improvements and to translate them into better solutions.<\/p>\n

We are committed to synergies between teams, to collaborations, as well as the reinvestment of profits in Spain as part of our contribution to the development of the National Health System.<\/p>\n<\/div>\n <\/div>\n

\n \"\"\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n

Mission<\/h2>\n
\n 2<\/span>\n \/\n 3<\/span>\n <\/div>\n <\/div>\n

We develop innovative products and services<\/strong> that represent a differential advantage for patients and our collaborators, always following the standards of quality and respect for the environment<\/strong>, and maintaining the corporate identity of the Gebro Pharma Holding.<\/p>\n<\/div>\n <\/div>\n

\n \"\"\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n

Values<\/h2>\n
\n 3<\/span>\n \/\n 3<\/span>\n <\/div>\n <\/div>\n

Our organizational culture and our value proposition to society are governed by six main values that were born from a joint co-creation between all Gebro Pharma employees. These values inspire our daily lives and constitute our way of being and working:<\/p>\n

– Effort and Commitment
\n– Kindness and Trust
\n– Innovation and Long-term vision<\/p>\n<\/div>\n <\/div>\n

\n \"\"\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n<\/section>\n\n\n
\n

History<\/h2>\n
These have been the main milestones of Gebro Pharma’s success:<\/div>\n \n
\n \n\n<\/svg>\n<\/div>\n Read more\n <\/a>\n \n
\n\n
\n
\n
\n
\n \n 1957-1968\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 1966\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 1976\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 1978\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 2000\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n Before 2012\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 2012\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 2017\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 2018\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 2019\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 2020\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 2021\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n 2022\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n
\n \"\"\n <\/div>\n
1957-1968<\/div>\n

Significant steps were taken for the future of the company<\/h3>\n
They signed licensing agreements with Swedish and German companies. They expanded and modernized their factory. They produced almost all galenic forms. In these years Gebro investigated the fluoride content of drinking water in Austria and discovered that it was very low. The company provided hundreds of thousands of fluoride-rich products for the prevention of caries for Austrian children.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
1966<\/div>\n

The R+D department was created<\/h3>\n
And innovative products emerge from it: in 1989 an anti-inflammatory product started being marketed, and later on in 1993 it was turn for a product indicated for central diabetes insipidus and primary enuresis (urinary incontinence) at night.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
1976<\/div>\n

Gebro went international<\/h3>\n
The company opened its doors first in Switzerland (1976), and years after in Spain (2002) and Hungary (2007).<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
1978<\/div>\n

Vital was refloated<\/h3>\n
Helga and Herbert, in response to a request from the Fieberbrunn City Council decided to refloat the \u201clight sandal\u201d manufacturer Vital.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
2000<\/div>\n

Alpinamed acquisition<\/h3>\n
Research was extended to Switzerland in Phytotherapy with the brand Alpinamed acquisition, specializing in the production of herbal extracts, medical devices and cosmetics of high quality.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
Before 2012<\/div>\n

Awards and recognitions<\/h3>\n
The Broschek family received, among others, the Medal of Honour of the Republic of Austria, the honorary citizenship of Fieberbrunn for Herbert Broschek, and the Tyrolean Cross of Merit for Helga Broschek.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
2012<\/div>\n

Gebro Holding GmbH was founded<\/h3>\n
<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \n <\/div>\n
2017<\/div>\n

Gebro Pharma signs an agreement with Richi Social Entrepreneurs<\/h3>\n
A collaboration established to detect and accompany innovative projects in the field of health through an immersion program in Boston.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \n <\/div>\n
2018<\/div>\n

Collaboration with Goodgut<\/h3>\n
We teamed up with the Catalan biotech Goodgut for a study on the treatment of Crohn’s disease.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
2019<\/div>\n

Collaboration with Hospital Cl\u00ednic of Barcelona<\/h3>\n
Our company starts to collaborate with the Hospital Cl\u00ednic of Barcelona and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) for the development of new therapies for glioblastoma; we strengthen our presence in Urogynecology with an innovation in non-invasive bladder instillation.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
2020<\/div>\n

We contribute to the Covid-19 pandemic fight<\/h3>\n
During the pandemic, Gebro collaborated in the fight against Coronavirus disease 2019 through the EPICOS study and drug donations.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
2021<\/div>\n

Great Place to Work and two key agreements<\/h3>\n
A fantastic year for Gebro, since we not only obtained the Great Place to Work and Best Workplaces certifications, but signed an agreement with Novartis for the commercialization of two drugs for asthma and an agreement with an Austrian Biotech for the development of a phase 2 drug.<\/div>\n <\/div>\n <\/div>\n
\n
\n
\n \"\"\n <\/div>\n
2022<\/div>\n

Barcelona Health Hub and new agreements<\/h3>\n
We enter the Barcelona Health Hub, a private non-profit association that promotes innovation in digital health and its transfer to the sector. The same year Gebro Pharma signs an agreement with Biotech company for the development of a digital solution for patients with asthma. <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n\n\n \n <\/section>\n\n\n
\n

Gebro Talent<\/h2>\n
\n
\n

Humanistic leadership is the cornerstone of our philosophy. Gebro Pharma’s strong commitment to gender and generational equality and parity starts with our Management Committee and extends to all the people who make up our talent team.<\/p>\n<\/div>\n

\n
\n \n
\n \n\n<\/svg>\n<\/div>\n Get to know us!\n <\/a>\n <\/div>\n
\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n
\n \n
\n
\n
\n \"\"\n
\n

Sergi Aulinas<\/h3>\n

General Manager<\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n \"\"\n
\n

Gustavo P\u00e9rez<\/h3>\n

Director of Commercial Operations<\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n \"\"\n
\n

Ivet Vall<\/h3>\n

Director of Business Development and Innovation<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n<\/section>\n\n\n

\n
\n
\n

\n Transparency and Ethics\n <\/h2>\n
\n

Transparency, ethics and honesty are core pillars of our corporate culture. These values underpin the strong bonds of trust we establish with healthcare professionals, stakeholders, patients, our team, and society as a whole.<\/p>\n\n \n

\n \n\n<\/svg>\n<\/div>\n Learn more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n \"\"\n <\/div>\n <\/section>\n\n\n\n
\n

News<\/h2>\n
\n
\n

Stay up to date with the latest news from Gebro Pharma.<\/p>\n<\/div>

\n
\n \n
\n \n\n<\/svg>\n<\/div>\n See all the news\n <\/a>\n <\/div>\n
\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n
\n
\n \n\n<\/svg>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n
\n \n
\n
\n
\n \n \"\"\n <\/a>\n
\n
\n
\n Corporate<\/a>\n June 09, 2023<\/span>\n <\/div>\n \n

BIT Pharma’s Nicaplant\u00ae implants, licensed in Spain by Laboratorios Gebro Pharma, achieve the EMA’s PRIME designation<\/h3>\n <\/a>\n <\/div>\n \n

Laboratorios Gebro Pharma, S.A. and BIT Pharma signed an agreement back in 2022 for the commercialization of Nicaplant\u00ae in Spain, subject to prior regulatory approval. The implants, currently in development, are intended to prevent cerebral vasospasm, a severe complication that occurs in a high percentage of patients who have suffered a subarachnoid hemorrhage. This type […]<\/p>\n \n

\n \n\n<\/svg>\n<\/div>\n Read more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n \n \"\"\n <\/a>\n
\n
\n
\n Press<\/a>\n January 19, 2024<\/span>\n <\/div>\n \n

Sergi Aulinas (Gebro Pharma): \u201cHay que actuar en el precio de los f\u00e1rmacos regulados esenciales para que sean rentables\u201d<\/h3>\n <\/a>\n <\/div>\n \n

El pasado mes de enero Sergi Aulinas, CEO de Gebro Pharma, realiz\u00f3 una entrevista con el peri\u00f3dico econ\u00f3mico Cinco D\u00edas. En ella cuenta un reciente relanzamiento de un producto de la compa\u00f1\u00eda, hecho posible gracias a un acuerdo coinversiones. Aulinas se\u00f1ala los desaf\u00edos en el acceso a nuevos medicamentos y aboga por una sanidad p\u00fablica […]<\/p>\n \n

\n \n\n<\/svg>\n<\/div>\n Read more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-8","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nAbout Gebro - Gebro Pharma<\/title>\n\n\n\n\n\n\n\n\n\n\n\t\n